Non Small Cell Lung Cancer Evaluation According to Pre-determined Drug-targeting Tumor Markers

Completed

• Conditions: Lung Cancer

• Registration Number: NCT01141686
• Lead Sponsor: Taipei Medical University WanFang Hospital

Brief Summary

Evaluate chemotherapy related tumor markers on non small cell lung cancer by fluorescent in situ hybridization and immunohistochemistry, targets to be studied include EGFR, c-MET, topoisomerase II, p53, topoisomerase I, thymidylate synthase, ERCC1, tau, c-myc, RRM1, class III tubulin. These targets have been chosen because they are targets for chemotherapeutic agents that are currently used in clinical management of these diseases. In total 50 specimen will be studied, approximately one third have mutations/deletions of the EGFR gene.To attempt to establish a correlation between the pre-selected tumor markers and response to chemotherapy, and thus to be able to create a clinically useful classification that would provide clinical guidance for selection of the most effective chemotherapy for a individual patient, and thus be able to logically design more effective clinical trials for the future.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-05
• Primary Completion: 2009-12
• Study Completion: 2009-12
• Status Verified: 2010-06
• Study First Submitted: 2010-06-08
• Study First Submitted QC: 2010-06-08
• Last Update Submitted: 2010-06-08
• Study First Posted: 2010-06-10
• Last Update Posted: 2010-06-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• Patients with histologically confirmed lung cancer who received standard platinum-containing doublet chemotherapy followed by EGFR tyrosine kinase inhibitors.

Exclusion Criteria

• non

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified